SCHEMBL26205834

SCHEMBL26205834

Cc1c(F)cc(NC2=CC(=O)N(c3ccc(F)cc3)C2=O)cc1F

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ KDM4E B2RXH2 4/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MGLL Q99685 1/20 0.40
▸ MAPT P10636 3/20 0.35
▸ HPGD P15428 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ POLB P06746 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ CACNA1B Q00975 1/20 0.33
▸ APBA1 Q02410 1/20 0.33
▸ KCNJ6 P48051 1/20 0.32
▸ KCNJ5 P48544 1/20 0.32
▸ KCNJ3 P48549 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26205855 0.93 MEN1 (0.52) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205843 0.91 MEN1 (0.68) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205886 0.91 KMT2A (0.50) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205804 0.90 MEN1 (0.49) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205783 0.89 MEN1 (0.43) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL26205848 0.89 ALDH1A1 (0.54) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205857 0.89 MEN1 (0.51) KMT2AMEN1KDM4EALDH1A1MGLL
SCHEMBL26205901 0.89 KMT2A (0.48) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL26205862 0.88 KMT2A (0.47) KMT2AMEN1KDM4EALDH1A1MAPT
SCHEMBL26205837 0.87 MEN1 (0.44) KMT2AMEN1KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease Southern Reserach Institute (US) 2023-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753374-B2 Compounds for the treatment of acute and chronic kidney disease HMOX1, GLS, HMOX2 KMT2A 2088/4885MEN1 4171/4885KDM4E 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback